VanEck Pharmaceutical ETF $PPH Shares Acquired by Citigroup Inc.

Citigroup Inc. grew its holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 987.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 718,199 shares of the company’s stock after acquiring an additional 652,175 shares during the period. Citigroup Inc. owned about 0.06% of VanEck Pharmaceutical ETF worth $64,896,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GSA Capital Partners LLP raised its holdings in shares of VanEck Pharmaceutical ETF by 214.1% during the third quarter. GSA Capital Partners LLP now owns 7,883 shares of the company’s stock worth $712,000 after purchasing an additional 5,373 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of VanEck Pharmaceutical ETF by 0.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 256,985 shares of the company’s stock valued at $23,221,000 after buying an additional 1,148 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of VanEck Pharmaceutical ETF by 305.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,014 shares of the company’s stock valued at $92,000 after buying an additional 764 shares during the period. Cibc World Market Inc. boosted its stake in shares of VanEck Pharmaceutical ETF by 5.1% in the third quarter. Cibc World Market Inc. now owns 4,282 shares of the company’s stock worth $387,000 after buying an additional 207 shares during the last quarter. Finally, Telos Capital Management Inc. grew its holdings in VanEck Pharmaceutical ETF by 38.2% during the third quarter. Telos Capital Management Inc. now owns 6,242 shares of the company’s stock worth $564,000 after acquiring an additional 1,726 shares during the period.

VanEck Pharmaceutical ETF Trading Up 0.5%

Shares of PPH stock opened at $110.90 on Tuesday. VanEck Pharmaceutical ETF has a twelve month low of $77.67 and a twelve month high of $112.58. The stock has a market cap of $1.22 billion, a P/E ratio of 20.21 and a beta of 0.54. The stock has a 50 day moving average of $106.32 and a 200 day moving average of $97.58.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 29th were given a $0.3106 dividend. The ex-dividend date was Monday, December 29th. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.1%.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.